Europace最新文献

{"title":"Elimination of epicardial late potentials by endocardial ablation in arrhythmogenic right ventricular cardiomyopathy.","authors":"Alexis Hermida, Chiara Pavone, Romain Sauve, Géraldine Vedrenne, Denis Amet, Matthieu Gras, Bruno Degand, Cyrus Moini, Guillaume Duthoit, Mikael Laredo, Nicolas Badenco, François Lesaffre, Antoine Lepillier, Françoise Hidden Lucet, Estelle Gandjbakhch, Xavier Waintraub","doi":"10.1093/europace/euag231","DOIUrl":"10.1093/europace/euag231","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous and Extravascular Implantable Cardioverter-Defibrillators: A Clinical Framework for Breast Surgery, Pregnancy, Lactation, Radiation Therapy, and Breast Imaging.","authors":"Kamala P Tamirisa, Ian Crozier, Lucas Boersma, Jodie L Hurwitz, Amin Al-Ahmad, Mark S Link, Miral Amin, Devika Adusumilli, Luigi DiBiase, Sana M Al-Khatib, Andrea M Russo","doi":"10.1093/europace/euag274","DOIUrl":"10.1093/europace/euag274","url":null,"abstract":"<p><p>The subcutaneous implantable cardioverter-defibrillator and extravascular implantable cardioverter-defibrillator do not require intravascular, intracardiac, or epicardial leads, making them attractive alternatives to transvenous implantable cardioverter defibrillators in patients without bradycardia pacing or cardiac resynchronization therapy indications. These systems are especially useful for patients with venous access challenges and those at risk for endovascular infections, including patients with renal failure or those who are immunocompromised. Women with prior or anticipated breast surgery, such as mastectomy or breast reconstruction surgery, or those who are lactating present unique anatomic, procedural, and post-operative quality-of-life considerations. This commentary provides a practical, scenario-based framework for managing this unique patient group. Key considerations include individualized incision and pulse generator planning, proactive multidisciplinary coordination, procedure-specific management, and shared decision-making in patients with prior or anticipated breast augmentation or reduction, pregnancy, lactation, mastectomy, radiation therapy, and breast imaging.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Left Atrial Ablation After Percutaneous Left Atrial Appendage Occlusion in High-Bleeding-Risk Patients with Atrial Fibrillation: A Multicenter Analysis from the PROCEED-AF Ablation Registry.","authors":"Rachel M Kaplan, Jeanne du Fay de Lavallaz, Christian-Hendrik Heeger, Hakan Oral, Mason Yoder, David Schaack, Julian K Chun, Boris Schmidt, Jeffrey Winterfield, William H Sauer, Fernando Moreno, Jonathan W Waks, Antonio Dello Russo, Paolo Compagnucci, Pipin Kojodjojo, Ghanshyam Shantha, Laurent Roten, Tobias Reichlin, Thomas Kueffer, Kenneth Brownell, Smit C Vasaiwala, Timothy M Markman, Patrick Badertscher, Michael Kühne, Christian Sticherling, Nishant Verma, Graham Peigh, Bradley P Knight, Tom De Potter, Konstantia Paraskevi Gkini, Dhiraj Gupta, Mark T Mills, Serge Boveda, Robin Richard-Vitton, Jorge Romero, Fengxiang Zhang, Raktham Mekritthikrai, Henry D Huang","doi":"10.1093/europace/euag277","DOIUrl":"https://doi.org/10.1093/europace/euag277","url":null,"abstract":"<p><strong>Background and aims: </strong>Patients with left atrial appendage (LAAO) devices are increasingly referred for AF ablation, yet anticoagulation strategies remain uncertain. The goal of this study was to evaluate the safety and efficacy of catheter ablation for atrial fibrillation (AF) in patients with pre-existing LAAO devices and to describe patterns in anticoagulation management after ablation in this unique population.</p><p><strong>Methods: </strong>We collected data from 14 centers worldwide on patients with prior LAAO devices undergoing AF ablation. Each site provided clinical characteristics, procedural details, and information on complications and arrhythmia outcomes. Data were aggregated and analyzed centrally to evaluate procedural safety, efficacy, and variability in management strategies.</p><p><strong>Results: </strong>A total of 198 patients (age 70 years, 37% female, 42% paroxysmal AF) with prior LAAO were included. Ablation was performed a median of 271 days after LAAO. After ablation, 84% of patients were on oral anticoagulation (OAC), most commonly for 2-3 months. Bleeding complications on OAC occurred in 6.7% of patients at a median of 20 (13, 70) days after ablation. Stroke or TIA occurred in 5 patients (2.6% of cases) within the follow-up period with 2 occurrences (1% of cases) the day after ablation. There were 2 cases of new or worsened peri-device leak after ablation.</p><p><strong>Conclusion: </strong>In a large, international registry of patients undergoing catheter ablation for AF with pre-existing LAAO devices, ablation was feasible and device related complications were rare Despite higher bleeding risk in an LAAO population, 84% of patients with prior LAAO tolerated short term OAC post-ablation with bleeding events at expected rates for this population.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nav1.5 Beyond Genetics: Loss of Cardiac Sodium-Channel Function in Brugada Syndrome.","authors":"Luigi Anastasia, Giuseppe Ciconte, Alessandro Fuga, Dudie Gjeci, Tiziano Dallavilla, Marco Piccoli, Federica Cirillo, Alessia Vuturo, Raffaele Salerno, Davide Morciano, Antonio Izzo, Marcello Manfredi, Carlo Pappone","doi":"10.1093/europace/euag261","DOIUrl":"https://doi.org/10.1093/europace/euag261","url":null,"abstract":"<p><p>Brugada syndrome is usually interpreted through SCN5A genetics, yet many patients with a Brugada phenotype carry no clearly pathogenic SCN5A variant and penetrance among carriers is incomplete. Cardiac sodium-channel function is therefore not a direct readout of coding sequence but an integrated property shaped by the channelosome, transcriptional and epigenetic control, post-translational modification, metabolic state, and inflammatory signaling. Through these routes, oxidative stress, altered glycosylation, and Nedd4-2-dependent ubiquitination can reduce peak sodium current in experimental systems, potentially lowering conduction reserve; inflammatory mediators may additionally modify the regional substrate through other ionic pathways without altering the SCN5A coding sequence in the experimental system, converging on the loss-of-function phenotype that characterizes Brugada syndrome, in contrast to the late-current gain of function of long QT syndrome type 3. Epicardial adipose tissue may provide a regional context for such signals at the right ventricular outflow tract, where conduction reserve is low and the substrate preferentially localizes, and anti-Nav1.5 autoantibodies provide a humoral route to reduced channel availability. We examine sequence-independent modifiers that may dynamically reduce Nav1.5 function and define the experimental framework needed to establish their clinical weight.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early rhythm control in patients with atrial fibrillation and cancer: A subgroup analysis of the EAST-AFNET 4 trial.","authors":"Djemail Ismaili, Anna Suling, Katrin Borof, Andreas Goette, Günter Breithardt, A John Camm, Harry Crijns, Lars Eckardt, Arif Elvan, Larissa Fabritz, Isabelle van Gelder, Michele Gulizia, Laurent Haegeli, Hein Heidbuchel, Josef Kautzner, Marc Lemoine, G André Ng, Renate B Schnabel, Lukasz Szumowski, Sakis Themistoclakis, Panos Vardas, Karl Wegscheider, Stephan Willems, Antonia Zapf, Andreas Metzner, Andreas Rillig, Paulus Kirchhof","doi":"10.1093/europace/euag269","DOIUrl":"https://doi.org/10.1093/europace/euag269","url":null,"abstract":"<p><strong>Background and aims: </strong>Early rhythm-control improves cardiovascular outcomes in patients with atrial fibrillation (AF). Its effectiveness in patients with cancer is unclear. This study evaluated the effects of cancer history on early rhythm-control in the EAST-AFNET 4 trial.</p><p><strong>Methods: </strong>This secondary analysis of EAST-AFNET 4 compared patients with and without a history of cancer, including active cancer and cancer in remission. Outcomes included the primary outcome, a composite of cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome; the safety outcome, a composite of death, stroke, and serious adverse events related to rhythm-control; and rhythm at 24 months.</p><p><strong>Results: </strong>Cancer history was available in 2779/2789 patients (99.6%). Cancer history was present in 216/2779 (7.8%; 19 with active cancer; mean age, 73 years; 95 [44%] women; mean CHA2DS2-VASc score, 3.5). During a follow-up to 8.6 years, early rhythm control reduced the primary outcome in patients with and without a history of cancer (pinteraction = .23) with high rates of sinus rhythm at 24 months (cancer: 84.9%, without cancer: 81.8%; pinteraction = .60). In patients with a cancer history, there was a signal for more safety outcomes with early rhythm control (early rhythm control 36/116 [31%] patients with event, 22 deaths; usual care 20/100 [20%] patients with event, 18 deaths; pinteraction = .055).</p><p><strong>Conclusions: </strong>Early rhythm control therapy appears effective in patients with AF and a history of cancer but may be less safe than in patients without cancer, in this hypothesis-generating analysis. This could be play of chance but warrants further research into the safety and efficacy of rhythm control therapy in patients with a cancer history.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yield of Atrial Fibrillation Screening according to Methodology and Patient Characteristics: An Individual Participant Data Meta-Analysis of 34,165 Individuals Screened for Atrial Fibrillation within the AFFECT-EU/AF-SCREEN Collaboration.","authors":"Lucas Y Xing, William F McIntyre, Johan Engdahl, Matthias Daniel Zink, Nikolaus Albert Helmut Marx, Emma Svennberg, Katrin Kemp Gudmundsdottir, Jelle C L Himmelreich, Giuseppe Boriani, Davide Antonio Mei, Daniel Engler, Steven R Steinhubl, Karl Georg Haeusler, Matthias Endres, Joan Montaner, Ben Freedman, Renate B Schnabel, Jeff S Healey, Jesper Hastrup Svendsen, Søren Zöga Diederichsen","doi":"10.1093/europace/euag256","DOIUrl":"https://doi.org/10.1093/europace/euag256","url":null,"abstract":"<p><strong>Backgrounds and aims: </strong>Atrial fibrillation (AF) screening may reduce adverse outcomes through early initiation of preventive treatment. However, more data are warranted to inform the yield of different screening strategies. This study aimed to evaluate how patient characteristics and screening methodologies influence screening yield.</p><p><strong>Methods: </strong>We conducted an individual participant data meta-analysis of 12 European and North American study cohorts, by using generalized linear mixed models with random intercept at study level.</p><p><strong>Results: </strong>In this meta-analysis of 34,165 participants screened for AF (age 73.4 ± 7.5 years and 53.5% female), the screening yield increased with more intensive approaches, ranging from 0.83% [95% confidence interval (CI): 0.24-2.87] in single-timepoint screening, to 5.06% [95% CI: 3.55-7.17] in intermittent (i.e. repeated single-timepoint) screening, 4.81% [95% CI: 3.79-6.08] in short-term continuous monitoring (≤30 days), and up to 30.39% [95% CI: 28.06-32.84] in long-term continuous monitoring (>30 days). Advanced age, male sex, hypertension, and heart failure (HF) were associated with detection. Significant interactions were observed between screening approach and age, sex, HF, CHADS2, and NT-proBNP. These risk factors had a stronger influence on AF detection with single-timepoint screening, compared with more intensive methods.</p><p><strong>Conclusions: </strong>In this meta-analysis, AF screening yield varied substantially by patient characteristics and screening approach. Advanced age, male sex, and HF were independently associated with greater AF detection, particularly in those having single-timepoint screening. Our findings support tailoring the screening approach to the individual target population in clinical practice. Further studies to assess clinical outcomes following screening are needed and underway.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation.","authors":"Abir Attia, Charles-Alexandre LeBlanc, Ewen Le Quilliec, Feng Xiong, Martin G Sirois, Jean-François Tanguay, Jean-Claude Tardif, Martin Aguilar, Roddy Hiram","doi":"10.1093/europace/euag242","DOIUrl":"10.1093/europace/euag242","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) is the most frequently diagnosed cardiac arrhythmia. Catheter ablation using radiofrequency cauterization (CA-RFC) performed in the left atrium (LA) aims to isolate electrical sources of AF. This intervention is accompanied by frequent AF recurrences affecting 10% of patients at 30 days and 50% at one-year post-procedure. It has been suggested that inflammation could contribute to AF-recurrence post-CA-RFC. Given its anti-inflammatory and cardioprotective properties, colchicine has been proposed as a potential treatment to prevent AF recurrence post-CA-RFC.</p><p><strong>Hypothesis: </strong>RFC can lead to atrial fibrosis, inflammation, and new-onset AF, which may be mitigated by colchicine.</p><p><strong>Methods and results: </strong>Male and female Wistar rats (225-275 g) were divided into four groups: Sham or RFC, with or without colchicine (0.25 mg/kg/8 h, intraperitoneally) starting 8 h before surgery until D1 post-procedure. Sham animals underwent surgery without RFC. Electrophysiology and echocardiography assessments were performed on days 1 (D1) and 3 (D3) post-RFC. Colchicine significantly lowered RFC-induced AF vulnerability, improved LA conduction velocity, reduced LA fibrosis, and attenuated LA inflammation post-procedure. Colchicine also prevented RFC-induced CD11c+ macrophages while promoting CD206+ recruitment in the LA.</p><p><strong>Conclusion: </strong>Colchicine started before RFC may be an innovative strategy to prevent the development of LA arrhythmogenic substrate post-procedure.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148929388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Algorithm-guided personalized pulsed field ablation for persistent atrial fibrillation: a prospective multicentre study with matched external comparison.","authors":"Frédéric Anselme, Decebal Gabriel Lațcu, Théo Méral, Arnaud Savoure, Serge Boveda, Pascal Defaye, Sandrine Venier, Grégoire Massoullié, Pierre Ollitrault, Olivier Thomas, Raphaël Al Hamoud, Maria-Alexandra Nicola, Corentin Chaumont","doi":"10.1093/europace/euag225","DOIUrl":"10.1093/europace/euag225","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13554798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COnCOmitaNt pulsed field ablation-based pUlmonary vein isolation and lefT atrial appendage closure: the COCONUT study.","authors":"Christian-Hendrik Heeger, Laurent Roten, Domenico Della Rocca, Vedran Velagić, Dhiraj Gupta, Tom De Potter, Christian Sticherling, Lukas Urbanek, Boris Schmidt, Abdul Shokor Parwani, Ignacio Garcia-Bolao, Rocco Arancio, Amr Nawar, Shibu Mathew, Jennifer Beney, Henning Rolfes, Kolya Sievert, Serge Boveda, Antoine Lepillier, Marjorie Niro, Reza Wakili, Alexander Steger, Ahmad Awada, Vedran Pasara, Grégoire Massoullié, Andrija Nekic, Maarten Vanhaverbeke, Alexandre Almorad, Romain Eschalier, Maxim Didenko, Marco Contarini, Lorenz Räber, Jan-Per Wenzel, Manuel Rattka, Daniel Scherr, Roland Richard Tilz, Martin W Bergmann","doi":"10.1093/europace/euag198","DOIUrl":"10.1093/europace/euag198","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) ablation by pulmonary vein isolation (PVI) and left atrial appendage closure (LAAC) are increasingly performed as standalone procedures. Given that PVI and LAAC share the same access route, a combined approach of pulsed field ablation (PFA)-based PVI and LAAC might be beneficial. The COCONUT study focused on safety, efficacy, and outcomes combining PVI by PFA with LAAC in one procedure.</p><p><strong>Methods: </strong>This is a retrospective, multinational registry study. The primary endpoints were the following: (1) primary safety endpoint: serious adverse events; and (2) primary efficacy endpoint: success of PVI and LAA closure defined as the ability to isolate all pulmonary veins and the successful closure of the LAA. For secondary endpoints, peri-procedural data and follow-up data were collected.</p><p><strong>Results: </strong>A total of 155 patients from 22 centres of nine European countries were treated by concomitant pentaspline catheter PFA-based PVI and LAAC. The mean CHA2DS2-VA score was 3.1 ± 1.4. The primary efficacy endpoint was achieved at 97.4% with successful PVI at 100% and successful LAAC in 151/155 patients (97.4%). The primary safety endpoint was observed in 3/155 patients (1.9%). Transoesophageal echocardiography and/or CCTA 67 ± 26 days after the procedure showed no device embolization and no device-related thrombus, 24/151 (15.9%) patients showed peri-device gaps of <5 mm while gaps of >5 mm have been observed in 3/151 (2.0%). Among 137/155 patients with available arrhythmia, a follow-up >6 months at 78.1% showed sinus rhythm.</p><p><strong>Conclusion: </strong>In this large multicentre study, concomitant PFA-based AF ablation and LAA closure proved to be feasible, effective, and safe and overall procedure duration was short.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":"28 9","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13555073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amiodarone dose to treat ventricular tachycardia in Chagas cardiomyopathy.","authors":"Henrique Horta Veloso, Mauro Felippe Felix Mediano","doi":"10.1093/europace/euag142","DOIUrl":"10.1093/europace/euag142","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":"28 9","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}